Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice.

J Immunother Cancer · 2025 · PMC11950992 · PMID 40139833

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

almost significantno p-value reported

In Vox-treated tumors, Ifn-b was upregulated in neutrophils and macrophages and Ifn-g (almost significant), Isg15 and Grzb in total immune cells.

also in 996 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.